Storia in 2 fonti

Competition for obesity drugs, clinical blind spots, and more news from ADA

You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference.

Raccontata da

statnews.com

fiercepharma.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo1 g fa

Competition for obesity drugs, clinical blind spots, and more news from ADA

You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference.

originale

fiercepharma.com4 h fa

With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race

It’s a sign of the times that this year’s American Diabetes Association (ADA) Scientific Sessions meeting in New Orleans featured more chatter on obesity drugs and pipeline programs than those spec | Eli Lilly emerged…

Leggi questa versione → originale

Timeline cronologica

venerdì 5 giugno 2026·statnews.com
Texas AG investigating energy drinks
The limitations of private health insurance, the quiet collapse of America's research ethics watchdog and other Morning Rounds news
venerdì 5 giugno 2026·statnews.com
Newer GLP-1s, pushback on research cuts, and a protest
You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference in New Orleans.

Competition for obesity drugs, clinical blind spots, and more news from ADA

Confronto fonti

Competition for obesity drugs, clinical blind spots, and more news from ADA

With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race

Timeline cronologica

Texas AG investigating energy drinks

Newer GLP-1s, pushback on research cuts, and a protest

Lilly shares safety, tolerability data on its next-gen obesity drug

Triple hormone receptors, a monthly obesity drug, and a bittersweet ending

Competition for obesity drugs, clinical blind spots, and more news from ADA

Major readouts from the annual diabetes conference

With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race